FDAnews
www.fdanews.com/articles/90191-rxbio-reports-data-on-radiation-countermeasure

RXBIO REPORTS DATA ON RADIATION COUNTERMEASURE

January 16, 2007

RxBio has announced that its lead product, RX100, has been shown to protect against lethal, whole-body radiation when administered before, during or up to several hours after exposure. Animal studies convincingly demonstrate that RX100 can prevent death if given before or during lethal radiation exposure or if administered within six hours after lethal, whole-body radiation exposure.

RX100 is an analog of an endogenous, prosurvival molecule that is metabolically stabilized that boosts natural mechanisms that promote and sustain cell survival while inhibiting programmed cell death, according to the company. While other agents shut down essential cellular-signaling mechanisms involved in radiation-induced cellular injury, RX100 is a specific activator of natural, nontoxic, protective mechanisms of cell survival.

RX100 is a small molecule that is stable at room temperature, has an excellent shelf life and can be formulated for a wide range of patient types-from infants to the elderly.

"This product appears unique as a radioprotectant in that it can be administered orally or by subcutaneous injection before, during, or up to six hours after exposure to lethal, whole-body radiation," RxBio Chairman and CEO W. Shannon McCool said.

Several federal agencies have expressed interest in this promising new compound and its unique mechanism of action, according to the company.